Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | DHPS | P49366 | 1/20 | 0.38 |
| ▸ | FGR | P09769 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TEC | P42680 | 1/20 | 0.38 |
| ▸ | BMX | P51813 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12956112 | 0.88 | BTK (0.52) | BTKRAB9ABMX | |
| SCHEMBL12956116 | 0.87 | BTK (0.50) | BTKRAB9ABMX | |
| SCHEMBL1038537 | 0.85 | BTK (0.56) | BTKRAB9ANPC1SRCTEC | |
| SCHEMBL1039140 | 0.83 | BTK (0.48) | BTKRAB9ABMX | |
| SCHEMBL1041076 | 0.82 | BTK (0.50) | BTKSRCTECBMX | |
| SCHEMBL1039939 | 0.82 | BTK (0.51) | BTKRAB9ANPC1SRCTEC | |
| SCHEMBL13044255 | 0.81 | BTK (0.42) | BTKRAB9ANPC1SRC | |
| SCHEMBL12956198 | 0.81 | CNR2 (0.53) | RAB9ANPC1 | |
| SCHEMBL1042485 | 0.81 | BTK (0.43) | BTKRAB9ANPC1SRCBMX | |
| SCHEMBL1040923 | 0.80 | BTK (0.42) | BTKRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079726-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7838523-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838523-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | BTK 1/4885RAB9A 2778/4885NPC1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.